Antitumor Effect of Spleen in Immunochemotherapy after gastrectomy for gastric cancer.

将OK-432注射到生长中的肿瘤中，可抑制BALB/c小鼠腹腔sc中同种结肠26肿瘤细胞的生长。OK-432与环磷酰胺（CY）联合治疗后，腹腔鳞癌的肿瘤生长明显小于OK-432或CY，且联合治疗组的%L3T4明显高于CY组。仅在联合治疗组，脾脏细胞%L3T4明显升高。联合治疗组脾细胞有体内肿瘤中和活性，但弱于OK-432组。第二个实验的目的是检验脾脏在免疫化疗中是否真的具有有效的免疫活性。联合治疗组在给予OK-432和cy后6小时或12小时行脾切除术，12小时组肿瘤生长小于6小时组。这些数据表明，在OK-432和cy联合治疗中，脾脏具有有效的免疫活性。我们进行了回顾性研究，以了解全胃切除术后脾脏与免疫化疗的关系。患者在II期和III期分为两组：脾切除组和脾保留组。各组患者又分为免疫治疗组和非免疫治疗组。脾切除组存活率低于保脾组。III期免疫治疗保脾组5年生存率为41.7%。III期脾切除组与非免疫治疗组相比有显著性增高。这些结果表明，脾脏是有效免疫治疗所必需的。

The growth of syngenic COLON 26 tumor ells inoculated in the abdominal s.c. of BALB/c mouse was depressed by injection of OK-432 into the growing tumor. The tumor growth inoculated in the abdominal s.c.and treated by combination therapy with OK-432 and cycolphosphamide(CY) was significantly smaller than treated by either OK-432 or CY.In the combination therapy group, %L3T4 was increased as that of CY group. And only in the combinationtherapy grouop, %L3T4 of spleen cells was significantly increased. Spleen cells of combination therapy group hadin vivo tumor neutralizing activity, though it was weaker than that of the OK-432 group.The aim of second experiment as to examine whether the spleenhad really effective immune activity on immunochemotherapy. In the combination therapy group, splenetomy was undertaken 6hrs or 12 hrs later after administration of OK-432 and CY.The tumorgrowth was smaller in the 12hrs group than in the 6hrs group.These data suggested the spleen had effective immune activity in the combination therapy with OK-432 and CY.The retrospectivestudy was undertaken to gain insight into the relationship between spleen and immunochemotherapy after total gastrectomy. The patients were stratified into two groupsin stage II and III : a splenectomized group and a spleen preserved group. Further-more the patients in each group were divided into immunotherapy group and non-immunotherapy group. Survivals of the splenectomized group waslower than spleen preserving group. The 5-year survival rate of the spleen preserved group with immunotherapy in stage III was 41.7%. It was significantly higher level compared with 0% of splenectomized group with nonimmunotherapy in stage III.These results suggest that the spleen is necessaryfor effective immunotherapy.